Product Information
XTAMPZA ER 27 MG CAPSULE is a brand product labeled by Collegium Pharmaceutical, Inc., priced at $15.8622 per EA under NDC 24510013010. Its NADAC has been published 407 times since Mar 22, 2017.
FDA first approved this application on Apr 26, 2016.
Strength
27 mg/1
Manufacturer
Collegium Pharmaceutical, Inc.NDC
24510013010
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
12/18/2024
Active Ingredients
OXYCODONEApproval Type
New Drug (NDA)
FDA Application
NDA208090FDA Approved
4/26/2016
On Market Since
5/10/2016
Pharmacological Classes
Price Statistics
The NADAC for XTAMPZA ER 27 MG CAPSULE has been published 407 times since Mar 22, 2017, and over the history we have for it it has risen 74.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.8622 per EA |
|---|---|
| All-time high | $15.8701 (Aug 14, 2024) |
| All-time low | $8.7693 (May 17, 2017) |
| Median price | $13.3879 |
| Average price | $12.8384 |
| Largest weekly change | +9.9% (Jan 1, 2020) |
| Weeks tracked | 407 |
| Tracking since | Mar 22, 2017 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+2.6%
5Y
+18.5%
All
+74.1%
Last surveyed Jan 1, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the OXYCODONE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Collegium Pharmaceutical, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
OXYCODONE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of XTAMPZA ER 27 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for XTAMPZA ER 27 MG CAPSULE, manufactured by Collegium Pharmaceutical, Inc., is $15.8622 per EA (NDC 24510013010), effective Jan 1, 2025.
How has the price of XTAMPZA ER 27 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for XTAMPZA ER 27 MG CAPSULE has risen 74.1%. It has been tracked across 407 weekly CMS publications since Mar 22, 2017.
What are the highest and lowest recorded NADAC prices for XTAMPZA ER 27 MG CAPSULE?
Since Mar 22, 2017, the NADAC for XTAMPZA ER 27 MG CAPSULE has ranged from a low of $8.7693 (May 17, 2017) to a high of $15.8701 (Aug 14, 2024), with a median of $13.3879 per EA.
Are there cheaper alternatives to XTAMPZA ER 27 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of XTAMPZA ER 27 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures XTAMPZA ER 27 MG CAPSULE?
XTAMPZA ER 27 MG CAPSULE (NDC 24510013010) is labeled by Collegium Pharmaceutical, Inc., and CMS classifies it as a brand product.